Aliophen-XP is a highly concentrated polyphenolic composition derived from Aliophen®, a patented formulation based on malt and hops (Patent No. 102017000096298). Developed to enhance the original formulation, Aliophen-XP is produced through a specialized process that removes components potentially interfering with the biological activity of the bioactive compounds naturally extracted from malt and hops.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 14 of 14
Direct quantification of the percentage of arabica in roasted and ground coffee blends of arabica/robusta by High Resolution Nuclear Magnetic Resonance spectroscopy (NMR), in solution and multivariate statistical analysis. Particularly, the metabolites content present in water extracts of coffee is analyzed and compared with NMR data of our database.
This proposal focuses on the preparation of biocoatings enriched with varying percentages of mint essential oil nanoparticles, followed by their application to potato tubers to limit sprouting and control the development of alkaloids, particularly solanine, a toxic substance for the body.
Method for extracting, with high yield, phycobiliproteins from cyanobacterial and/or algal biomass, obtaining aqueous extracts characterized by high concentration of pigments (4-5 mg/mL) and a purity, at least equal to food/cosmetic grade (P≥2).
Plants have a huge potential to contribute to the solution of a large number of issues facing the modern world, ranging from a poor crop yields and problems caused by global climate changing. Our team has been on the forefront of the PCR and NGS applications to plant responses to biotic and abiotic stress. As experts in genomics and plant pathology we are able to accelerate the understanding and use of plant genes and resources.
The proposal concerns the development of the G.A.T.CD4 (Gliadin-activated CD4+ T cells) method which allows, in peripheral blood, the identification of CD4+ T lymphocytes reactive to toxic peptides of gliadin, the main gluten protein of cereals.
Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.
Our proposal focuses on innovative formulations containing metallic complexes and plant extracts for diabetes treatment. The formulations were tested in vitro on human adipocyte cell models, showing a strong hypoglycemic effect due to the synergistic action of the two components. The plant extracts, derived from waste biomass of the agri-food industry, possess high antioxidant activity and interesting nutraceutical properties, due to their composition rich in polyphenols.
Celiac disease and non-celiac gluten sensitivity affect a large portion of the world population. Furthermore, the percentage of people who adopt the gluten free diet is constantly increasing because it is perceived to be healthier. We have previously developed a food grade enzymatic procedure (transamidation) for wheat flour capable of making gluten unable to induce the inflammatory response in the intestine of celiac disease patients.
The technology concerns planar optical antennas composed of thin metal films and dielectric materials for the efficient direction of the light emitted by light sources, such as fluorescent molecules and bio-markers. They consist of a reflector layer, adjacent to the substrate, and a director, semi-reflective, between which the emitter is positioned, integrated into a homogeneous dielectric layer.
Currently, liposomes (artificially synthesised vesicles) are widely used as carriers for a variety of molecules in the cosmetic and pharmaceutical industries. In the clinical applications, for instance, they are employed to encapsulate a range of substances, such as antibiotics, proteins, genetic material, vitamins and anti-cancer drugs.
AIS aim is a robotized inclinometer measurement in standard inclinometer boreholes. The deep measurements have multiple applications, including: evaluating the rate of deep-seated ground deformation in landslide areas, evaluating the volume of deep-seated landslides and assessing landslide hazards. The AIS is composed by an electronic control manager, an inclinometer probe and an electric motor equipped with a high precision encoder for handling and continuous control of the probe in the borehole.
Our treatment demonstrated the ability to kill metastatic human melanoma cells, for which there are very few effective therapeutic approaches. Use of a specific Essential Oil (EO) to inhibit the replication of human metastatic melanoma cells. This EO can be used both for direct application to the skin, and administered by mouth to reach both primary and metastatic melanomas.
Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.